Free Trial
NASDAQ:SXTP

60 Degrees Pharmaceuticals 11/20/2023 Earnings Report

60 Degrees Pharmaceuticals logo
$3.16 -0.01 (-0.32%)
Closing price 04/17/2025 04:00 PM Eastern
Extended Trading
$3.18 +0.01 (+0.47%)
As of 04/17/2025 06:16 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

60 Degrees Pharmaceuticals EPS Results

Actual EPS
-$1.50
Consensus EPS
-$1.30
Beat/Miss
Missed by -$0.20
One Year Ago EPS
N/A

60 Degrees Pharmaceuticals Revenue Results

Actual Revenue
$0.06 million
Expected Revenue
$0.08 million
Beat/Miss
Missed by -$20.00 thousand
YoY Revenue Growth
N/A

60 Degrees Pharmaceuticals Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

60 Degrees Pharmaceuticals' Q1 2025 earnings is scheduled for Wednesday, May 21, 2025, with a conference call scheduled on Wednesday, May 14, 2025 at 7:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

60 Degrees Pharmaceuticals Earnings Headlines

Something strange going on at Mar-a-Lago
A former government advisor says a $9 trillion AI breakthrough is nearing launch. It may become America’s biggest advantage in the race against China — and a handful of Musk-linked companies could benefit.
Penny Stocks To Keep An Eye On - April 8th
60 Degrees Pharmaceuticals, Inc.
See More 60 Degrees Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like 60 Degrees Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on 60 Degrees Pharmaceuticals and other key companies, straight to your email.

About 60 Degrees Pharmaceuticals

60 Degrees Pharmaceuticals (NASDAQ:SXTP), a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is headquartered in Washington, the District of Columbia.

View 60 Degrees Pharmaceuticals Profile

More Earnings Resources from MarketBeat